Johnson Yiu Nam Lau - Jun 17, 2022 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
CEO and Chairman of the Board, Director
Signature
/s/Steven Adams, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Jun 17, 2022
Transactions value $
$11,400
Form type
4
Date filed
6/21/2022, 04:13 PM
Previous filing
Jun 6, 2022
Next filing
Jul 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Award $11.4K +23.4K +0.69% $0.49* 3.41M Jun 17, 2022 Direct F1
holding ATNXQ Common Stock 679K Jun 17, 2022 By Avalon Biomedical (Management) Limited F2, F3
holding ATNXQ Common Stock 165K Jun 17, 2022 By Spouse F3
holding ATNXQ Common Stock 107K Jun 17, 2022 By Avalon Polytom (HK) Limited F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 1.2M Jun 17, 2022 Common Stock 1.2M $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 1.4M Jun 17, 2022 Common Stock 1.4M $7.50 Direct
holding ATNXQ Stock Option (Right to Buy) 1 Jun 17, 2022 Common Stock 1 $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 54.9K Jun 17, 2022 Common Stock 54.9K $9.00 By Avalon Biomedical (Management) Limited F2, F3
holding ATNXQ Stock Option (Right to Buy) 250K Jun 17, 2022 Common Stock 250K $17.30 Direct
holding ATNXQ Stock Option (Right to Buy) 250K Jun 17, 2022 Common Stock 250K $13.17 Direct F5
holding ATNXQ Stock Option (Right to Buy) 55K Jun 17, 2022 Common Stock 55K $7.32 Direct
holding ATNXQ Stock Option (Right to Buy) 300K Jun 17, 2022 Common Stock 300K $12.45 Direct F6
holding ATNXQ Stock Option (Right to Buy) 150K Jun 17, 2022 Common Stock 150K $3.80 Direct F7
holding ATNXQ Restricted Stock Units 150K Jun 17, 2022 Common Stock 150K Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
F2 Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Dr. Johnson Lau ("Dr. Lau") owns all of the outstanding interests in Creative Decade Global Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Lau serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
F3 Dr. Lau disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Lau is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F4 These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
F5 This option vests in four equal annual installments beginning on February 28, 2020.
F6 This option vests in four equal annual installments beginning on June 5, 2021.
F7 This option vests in four equal annual installments beginning on August 3, 2022.
F8 Each restricted stock unit represents a contingent right to receive one share of stock.
F9 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.